Nor-Noha

Nor-Noha

SCHEMBL4097591

N=C(NO)NCC[C@H](N)C(=O)O

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.42
GRM8 O00222 1/20 0.42
GRM6 O15303 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
CYP1A2 P05177 1/20 0.42
GRIK1 P39086 1/20 0.42
GRM5 P41594 1/20 0.42
GRIA1 P42261 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA3 P42263 1/20 0.42
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
GRIA4 P48058 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIK2 Q13002 1/20 0.42
GRIK3 Q13003 1/20 0.42
GRIN2B Q13224 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nor-Noha SCHEMBL14754841 1.00 GSR (0.42) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL448333 0.89 OTC (0.53) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL4393876 0.83 PMP22 (0.43) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL29533865 0.83 PMP22 (0.43) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL1344672 0.81 SLC1A2 (0.42) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL1345201 0.80 PMP22 (0.41) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL5246763 0.80 PMP22 (0.41) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL466338 0.80 PMP22 (0.48) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL574645 0.80 PMP22 (0.48) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL1527399 0.80 PMP22 (0.48) GSRGRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565517-B2 Cyclic peptide having CTLA-4 inhibitory activity and use thereof GENEFRONTIER CORPORATION (JP) 2026-03-03 US disclosed
EP-4043076-B1 CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF GENEFRONTIER CORP (JP) 2024-06-26 EP disclosed
US-20240092836-A1 CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF GENEFRONTIER CORPORATION (JP) 2024-03-21 US disclosed
EP-4043076-A1 CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF GeneFrontier Corporation (JP) 2022-08-17 EP disclosed
US-20090194124-A1 Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine MALLE GERARD 2009-08-06 US disclosed
US-20090139537-A1 HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE L'OREAL S.A. 2009-06-04 US disclosed
US-20050136017-A1 Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin L'OREAL S.A. (FR) 2005-06-23 US disclosed
US-20050129645-A1 Hair shaping composition comprising at least one non-hydroxide imine L'OREAL 2005-06-16 US disclosed
EP-1532963-A1 Composition for straightening the hair comprising at least one imine not being an hydroxide L'OREAL (FR) 2005-05-25 EP disclosed
EP-1532960-A1 Hair styling composition containing a non-hydroxide imine L'OREAL (FR) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092836-A1 CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF CXCL10, CXCR3, CXCR6 GSR 4766/4885GRM8 1858/4885GRM6 1934/4885
US-12565517-B2 Cyclic peptide having CTLA-4 inhibitory activity and use thereof CXCL10, MLX, MICA GSR 4749/4885GRM8 2508/4885GRM6 3440/4885
US-20090139537-A1 HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE KRT18, INMT, INHA GSR 1364/4885GRM8 786/4885GRM6 3187/4885
US-20090194124-A1 Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine KRT18, KIT, PRDM7 GSR 3504/4885GRM8 2546/4885GRM6 4111/4885
US-20050129645-A1 Hair shaping composition comprising at least one non-hydroxide imine KRT18, INHA, H1-5 GSR 3204/4885GRM8 2107/4885GRM6 3955/4885
US-20050136017-A1 Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin BHMT, KRT18, INMT GSR 352/4885GRM8 388/4885GRM6 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.